{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-137689","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.198219+00:00","generated_at":"2026-06-15T13:03:06.428582+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akebia Q1 net loss $26.2M; Auryxia revenue $34.8M; vadadustat approved in 32 countries","bullets":["Net loss of $26.2M improved from $62.4M in Q1 2022; total revenue $40.1M vs $61.7M.","Auryxia net product revenue $34.8M, down 15.9% YoY; company reaffirms 2023 guidance $175-180M.","European Commission approved Vafseo (vadadustat) for anemia in CKD dialysis patients; approved in 32 countries.","Expects FDA Formal Dispute Resolution response within next 30 days; positive alternative dosing study results.","Cash $57.0M; expects to fund operations for at least 12 months with cash and Auryxia revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-137689","json":"https://secwatch.observer/filing/0001193125-23-137689.json","markdown":"https://secwatch.observer/filing/0001193125-23-137689.md","text":"https://secwatch.observer/filing/0001193125-23-137689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/0001193125-23-137689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/d439043d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:03:06.428582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"804c670ce31faf2d2af8aef533e86354f24b4b1d","claim":"Akebia Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $40.1 million, net income $(26.2) million. Guidance reaffirmed.","evidence_excerpt":"Total revenue was $40.1 million in the first quarter of 2023 compared to $61.7 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/0001193125-23-137689-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$40.1 million"},{"label":"Net income","value":"$(26.2) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}